1. Home
  2. RDHL vs VERO Comparison

RDHL vs VERO Comparison

Compare RDHL & VERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • VERO
  • Stock Information
  • Founded
  • RDHL 2009
  • VERO N/A
  • Country
  • RDHL Israel
  • VERO Canada
  • Employees
  • RDHL N/A
  • VERO N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • VERO Medical/Dental Instruments
  • Sector
  • RDHL Health Care
  • VERO Health Care
  • Exchange
  • RDHL Nasdaq
  • VERO Nasdaq
  • Market Cap
  • RDHL 3.9M
  • VERO 4.3M
  • IPO Year
  • RDHL N/A
  • VERO N/A
  • Fundamental
  • Price
  • RDHL $1.88
  • VERO $2.32
  • Analyst Decision
  • RDHL
  • VERO
  • Analyst Count
  • RDHL 0
  • VERO 0
  • Target Price
  • RDHL N/A
  • VERO N/A
  • AVG Volume (30 Days)
  • RDHL 2.9M
  • VERO 55.4K
  • Earning Date
  • RDHL 09-05-2025
  • VERO 11-13-2025
  • Dividend Yield
  • RDHL N/A
  • VERO N/A
  • EPS Growth
  • RDHL N/A
  • VERO N/A
  • EPS
  • RDHL N/A
  • VERO N/A
  • Revenue
  • RDHL $9,550,000.00
  • VERO $60,107,000.00
  • Revenue This Year
  • RDHL $381.91
  • VERO N/A
  • Revenue Next Year
  • RDHL N/A
  • VERO $7.51
  • P/E Ratio
  • RDHL N/A
  • VERO N/A
  • Revenue Growth
  • RDHL 157.62
  • VERO N/A
  • 52 Week Low
  • RDHL $1.06
  • VERO $2.10
  • 52 Week High
  • RDHL $9.00
  • VERO $14.50
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 52.80
  • VERO 46.51
  • Support Level
  • RDHL $1.89
  • VERO $2.26
  • Resistance Level
  • RDHL $2.61
  • VERO $2.65
  • Average True Range (ATR)
  • RDHL 0.23
  • VERO 0.10
  • MACD
  • RDHL 0.01
  • VERO 0.00
  • Stochastic Oscillator
  • RDHL 22.22
  • VERO 13.98

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About VERO Venus Concept Inc.

Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.

Share on Social Networks: